Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis

• Status: Recruiting
• Trial end date: 2022-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, multicenter, and exploratory study. The aim of this study is to explore predictive factors of acute radiotherapy induced oral mucositis in nasopharyngeal carcinoma patients treated with radio-chemotherapy and reduce incidence of oral mucositis by using recombinant human interleukin -11.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Oprelvekin

Criteria

Inclusion Criteria:

1. Clinical diagnosis of nasopharyngeal carcinoma.

2. 8th version American Joint Committee on Cancer (AJCC) stage I-IVB.

3. Age must beetween 18-75.

4. Performance status must be 0 or 1 according to Eastern Cooperative Oncology Group.

5. Adequate bone marrow, renal, and hepatic function.

Exclusion Criteria:

1. chemotherapy with fluorouracil drugs; Allergies to recombinant human interleukin-11.

2. Treatment with palliative intent.;Previous malignancy.

3. Pregnancy or lactation.

4. A history of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes.

5. Diabetes, oral mucositis and senile dry stomatitis.

6. Any severe coexisting disease.